Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Orion

83.00 EUR+2.03 %7.10, 17.29
14,510 following

ORNBV

NASDAQ Helsinki

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Dividend
Investor views
Compare
+2.03 %
+4.01 %
+17.73 %
+15.76 %
+30.40 %
+20.12 %
+113.20 %
+145.05 %
+639.09 %

Orion operates in the pharmaceutical industry. The company conducts research and development of human and veterinary drugs, where the main focus is on diseases that affect the nervous system, as well as oncology and respiratory diseases. Today, the company's products are found on a global level, with the largest presence in the Nordic region and the rest of Europe. The company's head office is located in Espoo, Finland.

Read more
Market cap
11.71B EUR
Turnover
7.64M EUR
P/E (adj.) (26e)
20.17
EV/EBIT (adj.) (26e)
15.77
P/B (26e)
7.22
EV/S (26e)
5.53
Dividend yield-% (26e)
2.15 %
Coverage
Recommendation
Accumulate
Target price
83.00 EUR
Updated
19.07.2026
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 20.07.2026

Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
Orion Prepares for Pharmaceutical Growth with a Major Investment Among other things, the production of active pharmaceutical ingredients and quality assurance will be strengthened. According to Juhani Kankaanpää, who is responsible for Orion’s production and supply chain, the investment...
10/4/2026, 1:15 PM
by Dissidentti
12
Inderes Ensimmäinen potilas on saanut hoitoa Orion Pharman Faasi 1/2 -tutkimuksessa... ORION OYJ LEHDISTÖTIEDOTE 05.10.2026 KLO 15.00 Ensimmäinen potilas on saanut hoitoa Orion Pharman Faasi 1/2 -tutkimuksessa ODM-216-molekyylillä, joka on yhtiön ensimmäinen kliiniseen kehitysvaiheeseen...
10/5/2026, 12:51 PM
by veronmaksaja
9
[quote="veronmaksaja, post:804, topic:557"]\nOrion is paying a pretty steep price for buying back its shares. I doubt that buying at current prices is timed very wisely, or what do others think?\n[/quote]\n\nThis share buyback program isn’t a form of profit distribution; instead,...
9/26/2026, 12:31 PM
by Ilkka
8
Orion’s Head of IR Tuukka Hirvonen talked about Orion as an investment target
9/8/2026, 3:12 PM
by Sijoittaja-alokas
6
Tässä on vielä Antin kommentit tuohon tuoreimpaan uutiseen, kun biologinen syöpälääkeaihio etenee kliiniseen vaiheeseen. Inderes – 6 Oct 26 Orionin ensimmäinen biologinen syöpälääkeaihio etenee kliiniseen vaiheeseen -... Tutkimus selvittää aihion turvallisuutta ja alustavaa tehoa...
yesterday
by Sijoittaja-alokas
5
Here are Antti’s comments on the fact that Orion’s licensing partner Tenax Therapeutics’ phase 3 study did not meet its primary endpoint. Inderes – 11 Aug 26 Orion: Takaisku levosimendaanin faasi 3 -tutkimuksessa - Inderes Pidämme aihion tietä myyntilupaan epätodennäköisenä.
8/11/2026, 8:15 AM
by Sijoittaja-alokas
5
It’s not that simple. If a company doesn’t have much debt and lacks new investment opportunities, acting that way right now can be a good idea, especially if the company itself sees the stock as reasonably valued. We don’t know whether the share price will be 40 € or 160 €, or somewhere...
9/26/2026, 10:34 AM
by TitoK
3
Read more on our forum
Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
19.10
2026

Half year dividend

28.10
2026

Interim report Q3'26

17.2
2027

Annual report '26

Regulatory press release07.10.2026, 08.00

125,000 Orion Corporation A shares converted into B shares

Orion
Press release06.10.2026, 08.00

Orion Pharma announces agreement with Qilu Pharma Europe for pembrolizumab biosimilar for European market

Orion
Analyst Comment06.10.2026, 06.45 by
Antti Siltanen

Orions første biologiske kræftlægemiddelkandidat rykker videre til den kliniske fase

Studiet undersøger lægemiddelkandidatens sikkerhed og foreløbige effekt.

Orion

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release05.10.2026, 14.00

Orion Pharma announces first patient dosed in Phase 1/2 clinical trial of ODM-216, the company’s first biologic candidate to reach clinical testing

Orion
Regulatory press release30.09.2026, 08.05

Orion Corporation completed share acquisitions

Orion
Regulatory press release30.09.2026, 08.00

Orion Corporation: Acquisition of own shares during week 40, 2026

Orion
Regulatory press release25.09.2026, 18.00

Orion Corporation: Acquisition of own shares during week 39, 2026

Orion
Regulatory press release18.09.2026, 18.00

Orion Corporation: Acquisition of own shares during week 38, 2026

Orion
Regulatory press release11.09.2026, 18.00

Orion Corporation: Acquisition of own shares during week 37, 2026

Orion
Analyst Comment09.09.2026, 06.35

Børsurougen | Sundhed & Vækst og M&A 8.9.2026

Børsinvestorens ugentlige temaer Sundhed samt Vækst & M&A kan ses på inderesTV.

Aiforia TechnologiesTerveystaloOrionRelais GroupAspo
Regulatory press release04.09.2026, 18.00

Orion Corporation: Acquisition of own shares during week 36, 2026

Orion
Regulatory press release04.09.2026, 08.00

102,000 Orion Corporation A shares converted into B shares

Orion
Regulatory press release27.08.2026, 12.00

Orion Corporation to commence acquisition of own shares for its share-based incentive plans

Orion
Analyst Comment11.08.2026, 07.12 by
Antti Siltanen

Orion: Tilbageslag i fase 3-studie med levosimendan

Vi anser, at vejen til salgstilladelse for kandidaten er usandsynlig.

Orion
Regulatory press release10.08.2026, 13.05

Orion’s license partner Tenax Therapeutics’ Phase 3 LEVEL trial of oral levosimendan in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) did not reach its primary endpoint

Orion
Orion Q2'26: Engangsmedvind bidrog til topresultatet
Research20.07.2026, 07.00 by
Antti Siltanen

Orion Q2'26: Engangsmedvind bidrog til topresultatet

Omsætningsvækst og en stigning i royaltyprocenten understøttede et stærkt kvartal.

Orion
Orion, Webcast, Q2'26
Webcast17.07.2026, 13.00

Orion, Webcast, Q2'26

Orion
Regulatory press release17.07.2026, 11.00

Orion Group Half-Year Financial Report January–June 2026

Orion
Regulatory press release17.07.2026, 09.30

Orion Corporation’s financial reporting and Annual General Meeting in 2027

Orion
Regulatory press release15.07.2026, 08.00

45,611 Orion Corporation A shares converted into B shares

Orion